Chuck Boyars

Walgreens Boots Alliance in its pending $23.7 billion sale to Sycamore Partners.

Marathon Oil (NYSE: MRO) in its $22.5 billion all-stock sale to ConocoPhillips (NYSE: COP). The transaction closed unconditionally following an FTC second request investigation.

Southwestern Energy (NYSE: SWN) in its merger with Chesapeake Energy (NASDAQ: CHK) to create a $24 billion combined company, now known as Expand Energy (NASDAQ: EXE). The transaction closed unconditionally following an FTC second request investigation.

Southeastern Grocers in its sale of approximately 400 Winn-Dixie and Harveys Supermarket stores to ALDI and its sale of pharmacy assets to CVS and Walgreens.

Bristol-Myers Squibb (NYSE: BMY) in its $90 billion acquisition of Celgene (NYSE: CELG), which closed following an FTC second request investigation, and the company’s related $13.4 billion divestiture of Celgene’s OTEZLA® program to Amgen.

Energy Transfer (NYSE: ET) in its $7.1 billion acquisition of Crestwood Equity Partners (NYSE: CEQP).

Adenza, a Thoma Bravo portfolio company, in its $10.5 billion sale to NASDAQ.

Carlisle Companies (NYSE: CSL) in its $1.6 billion acquisition of Henry Company and its $2 billion sale of Carlisle Interconnect Technologies to Amphenol (NYSE: APH).

Callon Petroleum (NYSE: CPE) in its $4.5 billion all-stock sale to APA Corporation (NASDAQ: APA).

Option Care Health (NASDAQ: OPCH) in its proposed $3.6 billion merger with Amedisys (NASDAQ: AMED).

UnitedHealth Group (NYSE: UNH) in securing unconditional clearance for an acquisition following a second request investigation.

Thoma Bravo in its $2.3 billion acquisition of ForgeRock (NYSE: FORG), which closed following a DOJ second request investigation.

Constellation Brands in its contract and trademark dispute with Anheuser Busch InBev regarding Constellation’s production of Corona Hard Seltzer.

NexTier Oilfield Solutions (NYSE: NEX) in its $5.4 billion merger of equals with Patterson-UTI Energy (NASDAQ: PTEN).

Celanese (NYSE: CE) in its $11 billion acquisition of DuPont’s Mobility & Materials business, which closed following an FTC second request investigation and pursuant to an EU-ordered divestiture.

Noble Corporation (NYSE: NE) in its all-stock acquisition of Pacific Drilling and its merger with Maersk Drilling, which closed pursuant to a divestiture ordered by the U.K. Competition & Markets Authority.

Veritas Veterinary Partners, a Percheron Capital portfolio company, in its acquisition of veterinary hospitals from Ethos Veterinary Health pursuant to an FTC-ordered divestiture.

Prince International (now Vibrantz Technologies), an American Securities portfolio company, in its $2.1 billion acquisition of Ferro (NYSE: FOE), which closed following an FTC second request investigation, and the company’s related divestiture of its porcelain enamel business.

Crescent Energy (NYSE: CRGY) in its $815 million acquisition of Uinta Basin assets from Verdun Oil Company pursuant to an FTC-ordered divestiture.

Twilio (NYSE: TWLO) in its $750 million investment in and strategic partnership with Syniverse.

Fullscript, a portfolio company of HGGC and Snapdragon Capital Partners, in its acquisition of Emerson Ecologics.

Staples in its proposed acquisition of Office Depot.

LaserShip, an American Securities portfolio company, in its acquisition of OnTrac Logistics.

Thoma Bravo in its $12.3 billion acquisition of Proofpoint (NASDAQ: PFPT).

Thoma Bravo in its $10.2 billion acquisition of RealPage (NASDAQ: RP).

Centerbridge Partners in its acquisitions and combination of daVinci Payments and Wirecard North America, forming North Lane Technologies (now Onbe).

Delphi Technologies (NYSE: DLPH) in its $3.3 billion sale to BorgWarner (NYSE: BWA).

Ellie Mae, a Thoma Bravo portfolio company, in its $11 billion sale to Intercontinental Exchange (NYSE: ICE).

Bristow Group (NYSE: VTOL), a provider of industrial aviation services, in its all-stock merger with Era Group.

Ten-X, a Thomas H. Lee Partners portfolio company, in its $190 million sale to CoStar.

Liqui-Box, an Olympus Partners portfolio company, in its $585 million acquisition of DS Smith’s plastics division. The transaction closed following a DOJ second request investigation and in connection with the agreed divestiture of certain DS Smith assets.

A private equity sponsor in its acquisition of a hospice provider.

SoftBank Vision Fund in its investment in ParkJockey (now REEF Technology) and in ParkJockey’s acquisition (with Mubadala) of Citizens Parking and Imperial Parking.

PEC Safety, a Thoma Bravo portfolio company, in its merger with Veriforce.

Tronox (NYSE: TROX) in its $2.2 billion acquisition of Cristal’s titanium dioxide business, and litigation by the FTC seeking to block the transaction

Kofax, a Thoma Bravo portfolio company, in its $400 million acquisition of Nuance Document Imaging.

TriMedx, a TowerBrook Capital Partners portfolio company, in its $300 million acquisition of Aramark Healthcare Services.

Riskonnect, a Thoma Bravo portfolio company, in its acquisition of Marsh ClearSight.

Thoma Bravo in its acquisitions and merger of MeridianLink and CRIF Lending Solutions.

Creat Group (owner of Bio Products Laboratory) in its €940 million public takeover of Biotest.

Chesapeake IRB (now Advarra), a Linden Capital Partners portfolio company, in its merger with Schulman IRB

Huntsman (NYSE: HUN) in its proposed merger with Clariant to create a $20 billion combined company.

WellCare Health Plans (NYSE: WCG) in its $800 million acquisition of Universal American (NYSE: UAM).

Zydus Pharmaceuticals in civil litigation relating to alleged price-fixing of generic drugs.

Abbott Laboratories (NYSE: ABT) in its $25 billion acquisition of St. Jude Medical (NYSE: STJ), which closed following an FTC second request investigation, and its related $1.1 billion divestiture of assets to Terumo.*

Teladoc (NYSE: TDOC) in litigation against the Texas Medical Board successfully challenging the board’s actions to restrict competition.*

Gilead Sciences (NASDAQ: GILD) in winning dismissal of a purported class action alleging unfair competition and Affordable Care Act violations with respect to its Hepatitis C drugs.*

Goldman Sachs (NYSE: GS) in civil litigation and government investigations relating to residential mortgage-backed securities.*

*Prior to joining Kirkland

Cleary Gottlieb Steen & Hamilton LLP, Washington, D.C., 2014–2016

Sullivan & Cromwell LLP, New York, 2012–2013